Review article
Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis
Eficacia y seguridad de los inyectables inhibidores de la PCSK9 en el tratamiento de dislipidemias y la prevención de enfermedades cardiovasculares: una visión general de 86 revisiones sistemáticas y un metaanálisis en red
Konstantinos Pamporisa,b,
, Paschalis Karakasisb,c, Spyridon Simantirisa, Marios Sagrisa, Konstantinos I. Bougioukasb, Nikolaos Fragakisc, Dimitrios Tousoulisa
Corresponding author
a 1st Cardiology Clinic, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
b Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
c Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Greece